• G Paternoster, C Sartini, E Pennacchio, F Lisanti, G Landoni, and L Cabrini.
• Cardiovascular Anesthesia and ICU, San Carlos Regional Hospital (San Carlo Azienda Ospedaliera Regionale), Potenza, Italy.
• Med Intensiva. 2020 Sep 6.

ObjectiveContinuous positive airway pressure (CPAP) is an important therapeutic tool in COVID-19 acute respiratory distress syndrome (ARDS) since it improves oxygenation, reduces respiratory rate and can prevent intubation and intensive care unit (ICU) admission. CPAP during pronation has seldom been described and never during sedation.DesignCase series.SettingHigh dependency unit of San Carlo University Hospital (Potenza, Italy).PatientsEleven consecutive patients with COVID-19 ARDS.InterventionHelmet CPAP in prone position after failing a CPAP trial in the supine position.Main Variable Of InterestData collection at baseline and then after 24, 48 and 72h of pronation. We measured PaO2/FIO2, pH, lactate, PaCO2, SpO2, respiratory rate and the status of the patients at 28-day follow up.ResultsPatients were treated with helmet CPAP for a mean±SD of 7±2.7 days. Prone positioning was feasible in all patients, but in 7 of them dexmedetomidine improved comfort. PaO2/FIO2 improved from 107.5±20.8 before starting pronation to 244.4±106.2 after 72h (p<.001). We also observed a significantly increase in Sp02 from 90.6±2.3 to 96±3.1 (p<.001) and a decrease in respiratory rate from 27.6±4.3 to 20.1±4.7 (p=.004). No difference was observed in PaCO2 or pH. At 28 days two patients died after ICU admission, one was discharged in the main ward after ICU admission and eight were discharged home after being successfully managed outside the ICU.ConclusionsHelmet CPAP during pronation was feasible and safe in COVID-19 ARDS managed outside the ICU and sedation with dexmedetomidine safely improved comfort. We recorded an increase in PaO2/FIO2, SpO2 and a reduction in respiratory rate.Copyright © 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

19 keywords...

hide…